IP Library › Granted Patent US 12,268,780
Granted Patent B1
US 12,268,780 · App. 17/497,819 · Granted Apr 8, 2025

Transparent water nanolipid fluid (DNLF) dispersions and method of preparation using a twin screw extruder

Inventor: Eric Morrison (West Saint Paul, MN)
A61K9/1075A61K9/5123A61K9/5192A61K31/01A61K31/015A61K31/05A61K31/122A61K31/167A61K31/192A61K31/216A61K31/245A61K31/355A61K31/375A61K31/593A61K31/616A61K36/185A61K36/23A61K36/28A61K36/45A61K36/54A61K36/73A61K36/752B01F23/4105B01F23/4145B01F27/421B01F2101/22B01F2215/0431B01F2215/0472B01F2215/0481
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,780
App. No.
17/497,819
Granted
Apr 8, 2025
Kind
B1
Abstract

The present invention provides a method of preparing a lipid nanoparticle dispersion using a twin screw extruder. The inventive DNLF fluids are isotropic fluids which include greater than 25% lipophilic content in the form of lipidic nanoparticles dispersed in a continuous aqueous matrix with turbidity less than 375 nephelometric turbidity units (NTU).

Claims (36)

1. A lipid nanoparticle dispersion comprising:

from 11.1 to 19.8 wt. % of one or more polyethoxylated high hydrophile-lipophile-balance (HLB) surfactants selected from the group consisting of laureth-23, ceteareth-20, ceteareth-30, steareth-40, PEG32 stearate, PEG75 stearate, PEG100 stearate, PEG15 hydroxy stearate, PEG40 hydrogenated castor oil, polysorbate 20, polysorbate 80, and combinations thereof;

from 3.3 to about 10.1 wt. % of one or more low hydrophile-lipophile-balance (HLB) surfactants selected from the group consisting of cetyl alcohol, glyceryl oleate, glyceryl stearate, glyceryl monolinoleate, oleic acid, stearic acid, sorbitan oleate, soy lecithin, and combinations thereof;

one or more water immiscible oils selected from the group consisting of medium chain triglyceride oil, coconut oil, isopropyl palmitate, isopropyl myristate, methyl decanoate, ethyl myristate, ethyl oleate, mineral oil, orange essential oil, cyclopentasiloxane, poly(dimethyl siloxane), hexadecane, propylene glycol dicaprylate, isododecane, isoeicosane, isohexadecane, soy biodiesel, jojoba oil, cocoyl caprylocaprate, C 10 -C 13 alkane, squalane, sunflower seed oil, and combinations thereof; and

water,

wherein the lipid nanoparticle dispersion has a lipophilic concentration greater than about 25%, a volume average particle size less than about 100 nm, and a turbidity less than 375 nephelometric turbidity units (NTU) at room temperature.

2. The lipid nanoparticle dispersion of claim 1 , further comprising one or more hydrophobic drugs selected from the group consisting of aspirin, benzocaine, ibuprofen, lidocaine, and combinations thereof.

3. The lipid nanoparticle dispersion of claim 1 further comprising one or more hydrophobic therapeutic agents selected from the group consisting of ascorbyl palmitate, birch bark extract, cannabidiol, ubiquinone, cholecalciferol, tetrahydrocannabinol, humulene, myrcene, Litsea cubeba oil, limonene, cranberry seed oil, raspberry seed oil, black cumin seed oil, retinyl palmitate, tocopheryl acetate, tocopherol, and combinations thereof.

4. The lipid nanoparticle dispersion of claim 1 having a latent lamellar structure.

5. The lipid nanoparticle dispersion of claim 1 that is a non-equilibrium lipid nanoparticle dispersion.

6. The lipid nanoparticle dispersion of claim 1 , wherein a concentration of water immiscible non-amphipathic compounds is greater than about 20%.

7. The lipid nanoparticle dispersion of claim 1 , further comprising a non-ethoxylated high hydrophile-lipophile-balance (HLB) surfactant selected from the group consisting of sodium lauryl sulfate, sodium stearoyl lactylate, and combinations thereof.

8. The lipid nanoparticle dispersion of claim 1 having a turbidity less than 250 nephelometric turbidity units (NTU) at room temperature.

9. The lipid nanoparticle dispersion of claim 1 having a turbidity less than 125 nephelometric turbidity units (NTU) at room temperature.

10. The lipid nanoparticle dispersion of claim 1 that does not include one or more co-solvents.

11. The lipid nanoparticle dispersion of claim 1 that does not include ibuprofen.

12. The lipid nanoparticle dispersion of claim 1 that does not include lidocaine.

13. The lipid nanoparticle dispersion of claim 1 wherein the lipid nanoparticles are not vesicular nanoparticles.

14. The lipid nanoparticle dispersion of claim 1 having a latent lamellar structure wherein the lipid nanoparticles are not vesicular nanoparticles.

15. The lipid nanoparticle dispersion of claim 1 having a volume average particle diameter in a range from 23.6 nm to 58 nm.

16. The lipid nanoparticle dispersion of claim 1 , further comprising a cryoprotectant.

17. The lipid nanoparticle dispersion of claim 16 , wherein the cryoprotectant comprises 6 to 9.8 wt. % glycerin.

18. The lipid nanoparticle dispersion of claim 1 , comprising more than one high HLB surfactant.

19. The lipid nanoparticle dispersion of claim 1 , wherein the one or more water immiscible oils comprises cyclopentasiloxane.

20. The lipid nanoparticle dispersion of claim 1 , wherein the one or more water immiscible oils comprises mineral oil.

21. The lipid nanoparticle dispersion of claim 3 , wherein the one or more hydrophobic therapeutic agents comprises limonene.

22. The lipid nanoparticle dispersion of claim 1 having a turbidity in a range from 47 to 365 nephelometric turbidity units (NTU) at room temperature.

23. A lipid nanoparticle dispersion comprising:

from about 10 to about 15 wt. % of one or more polyethoxylated high hydrophile-lipophile-balance (HLB) surfactants selected from the group consisting of laureth-23, ceteareth-20, ceteareth-30, steareth-40, PEG32 stearate, PEG75 stearate, PEG100 stearate, PEG15 hydroxy stearate, PEG40 hydrogenated castor oil, polysorbate 20, polysorbate 80, and combinations thereof;

from about 8 to about 12 wt. % of one or more low hydrophile-lipophile-balance (HLB) surfactants selected from the group consisting of cetyl alcohol, glyceryl oleate, glyceryl stearate, glyceryl monolinoleate, oleic acid, stearic acid, sorbitan oleate, soy lecithin, and combinations thereof;

from about 20 to about 40 wt. % of one or more water immiscible oils selected from the group consisting of medium chain triglyceride oil, coconut oil, isopropyl palmitate, isopropyl myristate, methyl decanoate, ethyl myristate, ethyl oleate, mineral oil, orange essential oil, cyclopentasiloxane, poly(dimethyl siloxane), hexadecane, propylene glycol dicaprylate, isododecane, isoeicosane, isohexadecane, soy biodiesel, jojoba oil, cocoyl caprylocaprate, C 10 -C 13 alkane, squalane, sunflower seed oil, and combinations thereof; and

from about 35 to about 60 wt. % water,

wherein the lipid nanoparticle dispersion has:

a lipophilic concentration greater than about 25%;

a volume average particle size less than about 100 nm; and

a turbidity less than 375 nephelometric turbidity units (NTU).

Continuity (1)
Provisional Application 63089342 · Oct 8, 2020
References Cited (30)
US 20170296496A1 · Morrison · 2017 [cited by examiner]
Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. Jun. 2002;19(6):875-80. doi: 10.1023/a:1016121319668. PMID: 12134960. [cited by applicant]
Lamprecht A, Saumet J, Roux J, Benoit J. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int J Pharm . Jul. 8, 2004; 278 ( 2 ): 407-14. [cited by applicant]
Anton N, Gayet P, Benoit JP, Saulnier P. Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion. Int J Pharm. Nov. 1, 2007;344(1-2):44-… [cited by applicant]
Abdel-Mottaleb M, Neumann D, Lamprecht A. Lipid nanocapsules for dermal application: a comparative study of lipid—based versus polymer-based nanocarriers . Eur J Pharm Biopharm . Sep. 2011;79( 1): 36-42. [cited by applicant]
Hong SS, Kim SH, Lim SJ. Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes. Int J Pharm. Apr. 10, 2015;483(1-2):142-50. doi: 10.1016/j.ijpharm.2015.02.013. [cited by applicant]
Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Temoporfin-loaded invasomes: development, characterization and in vitro skin penetration studies. J Control Release. Apr. 7, 2008;127(1):59-69. doi: 10.1016/j.jconre… [cited by applicant]
Ishii F, Nii T. Properties of various phospholipid mixtures as emulsifiers or dispersing agents in nanoparticle drug carrier preparations. Colloids Surf B Biointerfaces. Apr. 10, 2005;41(4):257-62. doi: 10.1016/j.colsur… [cited by applicant]
Barenholz Y, “Doxil®—the first FDA-approved nano-drug: lessons learned,” I Control Release, Jun. 10, 2012 ; 160(2): 117-34. [cited by applicant]
Davies J. A quantitative kinetic theory of emulsion type , I. Physical chemistry of the emulsifying agent, Gas/Liquid and Liquid/Liquid Interface (Proceedings of the International Congress of Surface Activity (1957), pp… [cited by applicant]
Akzo Nobel Surface Chemistry LLC Technical Information bulletin “HLB & Emulsification—Description of Hydrophile, Lipophile Balance and use of HLB in Producing Emulsions,” Publication SC-11-02, © 2011 Akzo Nobel Surface … [cited by applicant]
Forgiarini A, Esquena J, Gonzalez-Azon C, Solans C. Formation of Nano-emulsions by Low-Energy Emulsification Methods at Constant Temperature. Langmuir. 17. 10.1021/la001362n. Langmuir 2001, 17, 7, 2076-2083. doi: https:… [cited by applicant]
Formiga FR, Fonseca IA, Souza KB, Silva AK, Macedo JP, Araújo IB, Soares LA, Egito ES. Influence of a lipophilic drug on the stability of emulsions: an important approach on the development of lipidic carriers. Int J Ph… [cited by applicant]
Salim N, Basri M, Abdullah D, Bin Basri H, Hamidon. Phase Behaviour, Formation and Characterization of Palm-Based Esters Nanoemulsion Formulation containing Ibuprofen. Journal of Nanomedicine & Nanotechnology. doi: 10.4… [cited by applicant]
Lee HS, Morrison ED, Zhang Q, McCormick AV. Cryogenic transmission electron microscopy study: preparation of vesicular dispersions by quenching microemulsions. J Microsc. Sep. 2016;263(3):293-9. doi: 10.1111/jmi.12392. … [cited by applicant]
Lee HS, Morrison ED, Frethem CD, Zasadzinski JA, McCormick AV. Cryogenic electron microscopy study of nanoemulsion formation from microemulsions. Langmuir. Sep. 16, 2014;30(36):10826-33. doi: 10.1021/la502207f. Epub Sep… [cited by applicant]
Cevc G, Schätzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim… [cited by applicant]
Panigrahi L, Pattnaik S, Ghosal SK. The effect of pH and organic ester penetration enhancers on skin permeation kinetics of terbutaline sulfate from pseudolatex-type transdermal delivery systems through mouse and human … [cited by applicant]
Mahamongkol H, Bellantone RA, Stagni G, Plakogiannis FM. Permeation study of five formulations of alpha-tocopherol acetate through human cadaver skin. J Cosmet Sci. Mar.-Apr. 2005;56(2):91-10 DOI: 10.1111/j.0142-5463.20… [cited by applicant]
Wilkerson VA. The Chemistry of Human Epidermis: II. The Isoelectric Points of the Stratum Corneum, Hair, and Nails as Determined by Electrophoresis. , J. Biol. Chem ., 1935 , 112 :329-335. [cited by applicant]
Ali SM, Yosipovitch G. Skin pH: from basic science to basic skin care. Acta Derm Venereol. May 2013;93(3):261-7. doi: 10.2340/00015555-1531. [cited by applicant]
Bauer, J. (1994). Cell Electrophoresis (1st ed.). CRC Press. https://doi.org/10.1201/9781003069188. [cited by applicant]
Schambil F, Jost F, Schwuger M. Interfacial and colloidal properties of cosmetic emulsions containing fatty alcohol and fatty alcohol polyglycol ethers. In: Hoffmann, H. (eds) New Trends in Colloid Science. Progress in … [cited by applicant]
Izquierdo P, Esquena J, Tadros TF, Dederen JC, Feng J, Garcia-Celma MJ, Azemar N, Solans C. Phase behavior and nano-emulsion formation by the phase inversion temperature method. Langmuir. Aug. 3, 2004;20(16):6594-8. doi… [cited by applicant]
Sagitani H. Making homogeneous and fine droplet O/W emulsions using nonionic surfactants. J Am Oil Chem Soc 58, 738-743 (1981). https://doi.org/10.1007/BF02899466. [cited by applicant]
Solè I, Maestro A, Gonzalez C, Solans C, Gutiérrez JM. Optimization of nano-emulsion preparation by low-energy methods in an ionic surfactant system. Langmuir. Sep. 26, 2006;22(20):8326-32. doi: 10.1021/la0613676. [cited by applicant]
Fernandez F, André V, Rieger J, Kühnle A. Nano-emulsion formation by emulsion phase inversion, Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 251, Issues 1-3, 2004, pp. 53-58 https://doi.org/10.1… [cited by applicant]
Porras M, Solans C, González C, Solans C, Gutiérrez J. Properties of water-in-oil (W/O) nano-emulsions prepared by a low-energy emulsification method. Colloids and Surfaces A: Physicochem. Eng. Aspects 324 (2008) 181-18… [cited by applicant]
Solans C, Solè I, Fernández-Arteaga A, Nolla J, Azemar N, Gutiérrez J, Maestro A, González C, Pey C. Nano-Emulsion Formation by Low-Energy Methods and Functional Properties. Structure and Functional Properties of Colloi… [cited by applicant]
Salim, Norazlinaliza et al, “Modification of palm kernel oil esters nanoemulsions with hydrocolloid gum for enhanced topical delivery of ibuprofen,” International Journal of Nanomedicine, 2012:7 4739-4747. [cited by applicant]
Cited By (2)
US 12,605,394 US 12,667,578